Genotypic resistance profiles of HIV-2-infected patients from Cape Verde failing first-line antiretroviral therapy

Inês Moranguinho; Pedro Borrego; Fátima Gonçalves; Perpétua Gomes; José Rocha; Jorge Barreto; Nuno Taveira

doi:10.1097/QAD.0000000000002431

Genotypic resistance profiles of HIV-2-infected patients from Cape Verde failing first-line antiretroviral therapy

Inês Moranguinho, Pedro Borrego, Fátima Gonçalves, Perpétua Gomes, José Rocha, Jorge Barreto, Nuno Taveira

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

The pol gene from HIV-2-infected patients from Cape Verde experiencing virologic failure was sequenced and drug resistance mutations were determined. Most patients were taking a first-line regimen of zidovudine (AZT), lamivudine (3TC) and lopinavir/ritonavir (LPV/r). Resistance mutations were found in most patients (11/17; 64.7%) especially I82F (4/7; 57.1%) and M184V (10/17; 58.8%). Resistance to all reverse transcriptase and protease inhibitors was found in 58.8% (10/17) of the patients. Integrase inhibitors are warranted to treat these patients.

Original language	English
Pages (from-to)	483-486
Number of pages	4
Journal	AIDS
Volume	34
Issue number	3
DOIs	https://doi.org/10.1097/QAD.0000000000002431
Publication status	Published - 1 Mar 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/QAD.0000000000002431

Cite this

@article{0ea1f7c27e484b2393f7495f7ef9b31b,

title = "Genotypic resistance profiles of HIV-2-infected patients from Cape Verde failing first-line antiretroviral therapy",

abstract = "The pol gene from HIV-2-infected patients from Cape Verde experiencing virologic failure was sequenced and drug resistance mutations were determined. Most patients were taking a first-line regimen of zidovudine (AZT), lamivudine (3TC) and lopinavir/ritonavir (LPV/r). Resistance mutations were found in most patients (11/17; 64.7%) especially I82F (4/7; 57.1%) and M184V (10/17; 58.8%). Resistance to all reverse transcriptase and protease inhibitors was found in 58.8% (10/17) of the patients. Integrase inhibitors are warranted to treat these patients.",

author = "In{\^e}s Moranguinho and Pedro Borrego and F{\'a}tima Gon{\c c}alves and Perp{\'e}tua Gomes and Jos{\'e} Rocha and Jorge Barreto and Nuno Taveira",

year = "2020",

month = mar,

day = "1",

doi = "10.1097/QAD.0000000000002431",

language = "English",

volume = "34",

pages = "483--486",

journal = "AIDS",

issn = "0269-9370",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Genotypic resistance profiles of HIV-2-infected patients from Cape Verde failing first-line antiretroviral therapy

AU - Moranguinho, Inês

AU - Borrego, Pedro

AU - Gonçalves, Fátima

AU - Gomes, Perpétua

AU - Rocha, José

AU - Barreto, Jorge

AU - Taveira, Nuno

PY - 2020/3/1

Y1 - 2020/3/1

N2 - The pol gene from HIV-2-infected patients from Cape Verde experiencing virologic failure was sequenced and drug resistance mutations were determined. Most patients were taking a first-line regimen of zidovudine (AZT), lamivudine (3TC) and lopinavir/ritonavir (LPV/r). Resistance mutations were found in most patients (11/17; 64.7%) especially I82F (4/7; 57.1%) and M184V (10/17; 58.8%). Resistance to all reverse transcriptase and protease inhibitors was found in 58.8% (10/17) of the patients. Integrase inhibitors are warranted to treat these patients.

AB - The pol gene from HIV-2-infected patients from Cape Verde experiencing virologic failure was sequenced and drug resistance mutations were determined. Most patients were taking a first-line regimen of zidovudine (AZT), lamivudine (3TC) and lopinavir/ritonavir (LPV/r). Resistance mutations were found in most patients (11/17; 64.7%) especially I82F (4/7; 57.1%) and M184V (10/17; 58.8%). Resistance to all reverse transcriptase and protease inhibitors was found in 58.8% (10/17) of the patients. Integrase inhibitors are warranted to treat these patients.

UR - http://www.scopus.com/inward/record.url?scp=85078692728&partnerID=8YFLogxK

U2 - 10.1097/QAD.0000000000002431

DO - 10.1097/QAD.0000000000002431

M3 - Article

C2 - 31764077

AN - SCOPUS:85078692728

SN - 0269-9370

VL - 34

SP - 483

EP - 486

JO - AIDS

JF - AIDS

IS - 3

ER -

Genotypic resistance profiles of HIV-2-infected patients from Cape Verde failing first-line antiretroviral therapy

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this